Log in
(Ad)
Your 401(k) or IRA account could be in double-trouble in 2020! With a slowing global economy and the uncertainty of a national election looming, it's time to PLAY DEFENSE with your hard-earned money. Employ a winning strategy for wealth protection and portfolio diversification to avoid the coming rush of economic risk.

NASDAQ:EPOC - Epocrates Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume228,735 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Epocrates, Inc (Epocrates) is a provider of mobile drug reference tools and electronic health records to healthcare professionals and interactive services to the healthcare industry. As of December 31, 2011, its user network consists of well over one million healthcare professionals, including approximately 340,000, or more than 50% of United States physicians. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:EPOC
Previous Symbol
CUSIPN/A
CIK1096738
Webhttp://www.epocrates.com/
Phone+1-415-4163500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive EPOC News and Ratings via Email

Sign-up to receive the latest news and ratings for EPOC and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Epocrates (NASDAQ:EPOC) Frequently Asked Questions

What is Epocrates' stock symbol?

Epocrates trades on the NASDAQ under the ticker symbol "EPOC."

Has Epocrates been receiving favorable news coverage?

News coverage about EPOC stock has trended negative on Thursday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Epocrates earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Epocrates.

What is Epocrates' official website?

The official website for Epocrates is http://www.epocrates.com/.

How can I contact Epocrates?

Epocrates' mailing address is 50 Hawthorne, SAN FRANCISCO, CA 94105, United States. The company can be reached via phone at +1-415-4163500.


MarketBeat Community Rating for Epocrates (NASDAQ EPOC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Epocrates and other stocks. Vote "Outperform" if you believe EPOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Is a Roth IRA right for you?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel